CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishGlioblastoma multiforme (GBM), a malignant tumor of the central nervous system, has a high mortality rate; no curativetreatment is presently available and the most commonly used chemiotherapeutic drug, the alkylating agent temozolomide (TMZ), is only able to increase life expectancy and is often associated with drugresistance. Therefore, an urgent need does exist for novel drugs aimed at treating gliomas. In the present study we obtained three major results using corliagin: (a) demonstrate that it inhibits the growth of U251 glioma cells through activation of the apoptotic pathway; (b) demonstrate that it is also active on temozolomideresistant T98G glioma cells; (c) demonstrate that when used in combination with temozolomide on T98G glioma cells a higher level of pro-apototic and antiproliferative effects are observed. Our study indicates that corilagin should be investigated in more detail in order to determine if it can be developed as a potential therapeutic agent. In addition, our results suggest that corilagin could be used in combination with low dosages of other standard anticancer chemotherapeutic drugs against gliomas (such as temozolomide) with the aim of obtaining enhanced anticancer effects.
| Data di pubblicazione: | 2018 | |
| Titolo: | Corilagin Induces High Levels of Apoptosis in the Temozolomide-Resistant T98G Glioma Cell Line | |
| Autori: | Milani, Roberta; Brognara, Eleonora; Fabbri, Enrica; Finotti, Alessia; Borgatti, Monica; Lampronti, Ilaria; Marzaro, Giovanni; Chilin, Adriana; Lee, Kenneth Ka-Ho; Kok, Stanton Hon-Lung; Chui, Chung-Hin; Gambari, Roberto | |
| Rivista: | ONCOLOGY RESEARCH | |
| Keywords: | Glioma, corilagin, temozolomide, apoptosis | |
| Abstract in inglese: | Glioblastoma multiforme (GBM), a malignant tumor of the central nervous system, has a high mortality rate; no curativetreatment is presently available and the most commonly used chemiotherapeutic drug, the alkylating agent temozolomide (TMZ), is only able to increase life expectancy and is often associated with drugresistance. Therefore, an urgent need does exist for novel drugs aimed at treating gliomas. In the present study we obtained three major results using corliagin: (a) demonstrate that it inhibits the growth of U251 glioma cells through activation of the apoptotic pathway; (b) demonstrate that it is also active on temozolomideresistant T98G glioma cells; (c) demonstrate that when used in combination with temozolomide on T98G glioma cells a higher level of pro-apototic and antiproliferative effects are observed. Our study indicates that corilagin should be investigated in more detail in order to determine if it can be developed as a potential therapeutic agent. In addition, our results suggest that corilagin could be used in combination with low dosages of other standard anticancer chemotherapeutic drugs against gliomas (such as temozolomide) with the aim of obtaining enhanced anticancer effects. | |
| Digital Object Identifier (DOI): | 10.3727/096504017X14928634401187 | |
| Handle: | http://hdl.handle.net/11392/2382172 | |
| Appare nelle tipologie: | 03.1 Articolo su rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| CORILAGIN INDUCES HIGH LEVELS OF APOPTOSIS IN THE TEMOZOLAMIDE-RESISTANT T98G GLIOMA CELL LINE.pdf | Full text editoriale | Full text (versione editoriale) | PUBBLICO - Pubblico con Copyright | Open Access Visualizza/Apri |
Copyright © 2022